David S. Bredt

From Wikipedia, the free encyclopedia

David S. Bredt is an American molecular neuroscientist who is an Executive Partner at investment firm MPM Capital since 2021.[1]

After studies in chemistry at Princeton, Bredt studied medicine at Johns Hopkins School of Medicine where he obtained M.D and Ph.D degrees. He was a student of Solomon H. Snyder, with whom he also co-authored several widely cited papers.[2]

He worked as a postdoctoral fellow in the Department of Neuroscience at Johns Hopkins from 1993 to 1994.[3] He became a 1995 Searle scholar,[4] and received a 1997 Beckman Young Investigators Award.[5]

He worked at the University of California, San Francisco Medical school from 1994 to 2004, first as an assistant professor,[2] later as professor of physiology.[3]

He served as Vice President of Integrative Biology at Eli Lilly and Company from 2004 to 2011.[6] He was elected to the Johns Hopkins University Society of Scholars in 2005.[3][7]

He worked at Johnson & Johnson from 2011 to 2021 as Global Head Discovery Neuroscience.[8]

On November 17, the Wall Street Journal published a story outing Dr. Bredt as allegedly co-author to an anonymous "Citizen's Petition" to the FDA to halt phase 3 trials of Simufilam, a drug targeting protein misfolding for treatment of Alzheimer's Disease which had recently published cognition improvements during phase two trials without safety issues.[9] Although this Citizen's Petition claimed to be by an anonymous whistleblower, the law firm filing the petition later acknowledged its clients had taken short positions in the company behind Simufilam before the Citizens Petition published and the share price crashed (and the aforementioned WSJ article later disclosed Dr. Bredt as co-author). Additionally on November 17, MPM Capital (Dr. Bredt's employer) was noted in a press release as funding Protego, a startup targeting protein misfolding potentially as a treatment for Alzheimer's Disease (which is also the mechanism of action of Simufilam).[10] Further on November 17, Dr. Bredt coauthored a 29-page supplement to the Citizen's Petition again pushing the FDA to halt phase 3 trials of Simufilam and citing the Wall Street Journal article (first published hours earlier) as part of its justification for demanding the halt of Simufilam trials.[11]

Selected papers[]

References[]

  1. ^ MPM Capital strengthens team with addition of neuroscience R&D leader David S. Bredt MD PhD as Executive Partner Retrieved 18 November 2021
  2. ^ a b Karen Kreeger (2 May 1992) Hot Scientists Have Philosophies In Common The Scientist
  3. ^ a b c Society of Scholars Inducts New Members The JHU Gazette. 23 May 2005. Retrieved 16 December 2013
  4. ^ Scholar Profile David S. Bredt
  5. ^ "David S. Bredt". Arnold and Mabel Beckman Foundation. Retrieved 1 August 2018.
  6. ^ Jonathan D. Rockoff (24 February 2011) Lilly's Neuroscience Research Chief Resigns The Wall Street Journal. Retrieved 16 December 2013
  7. ^ Julie Blanker (September 2005) Alumni NotesAlumni Notes Johns Hopkins Magazine. Retrieved 16 December 2013
  8. ^ Jonathan D. Rockoff (3 March 2011 J&J Poaches Lilly's Neurological Research Chief The Wall Street Journal. Retrieved 16 December 2013
  9. ^ Dave Michaels (November 2021) [1] "Wall Street Journal". Retrieved 7 December 2021
  10. ^ Protego BioPharma [2] "Global Newswire". Retrieved 7 December 2021
  11. ^ Third Supplement from Labaton Sucharow to Citizens Petition Associated with Cassava Sciences Inc (November 2021) [3] "FDA Dockets". Retrieved 7 December 2021
Retrieved from ""